glp-1 and pancreatitis The pancreatic extrapancreatic effect of GLP-1. GLP-1, glucagon factors that increase pancreatitis risk

Shao S, Nie M, Chen C, Chen X, Zhang M, Yuan G, Yu X, Yang Y

Beneficial effects of GLP-1 in reducing toxic protein accumulation are hypothesized to occur through the PI3K/Akt inactivation of glycogen synthase kinase 3 beta (GSK3) [82] and a possible GLP-1 mediated upregulation of IDE [83]

Warning letters in 2024 The FDAs Center for Devices and Radiological Health (CDRH) issued 529 warning letters in 2024,[1] most related to drugs, tobacco products or food products

The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes

There is no required washout period between stopping phentermine and starting a GLP-1, though your physician may want to confirm that cardiovascular parameters (heart rate, blood pressure) have returned to baseline before initiating new treatment

In addition, Ozempic and Mounjaro have FDA approval for type 2 diabetes blood sugar control but are often prescribed off-label for weight loss